Physician profile
Leandre W Odom
NPI 1003846809
$1,269.87
in general payments reported to CMS, 2019-2025
15 companies · $138 in 2025
The $138 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $118 · 2020: $213 · 2021: $90.94 · 2022: $206 · 2023: $122 · 2024: $383 · 2025: $138.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $642.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $421.14 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $214.29 | 2020-2025 | Jardiance, Mounjaro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.42 | 2020-2025 | Ofev |
| Glaxosmithkline, LLC. | $115.92 | 2019-2025 | Trelegy Ellipta |
| Pfizer INC. | $113.66 | 2019-2024 | |
| Novo Nordisk INC | $76.63 | 2019-2022 | |
| Ardelyx, INC. | $42.43 | 2024-2025 | Ibsrela |
| Abbvie INC. | $33.39 | 2024 | |
| Allergan, INC. | $25.61 | 2019 | |
| Astellas Pharma US INC | $21.49 | 2024 | Veozah |
| Abbott Laboratories | $21.22 | 2024 | Freestyle Libre 3 |
| Dexcom, INC. | $18.11 | 2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $15.59 | 2020 | |
| Exact Sciences Corporation | $14.51 | 2025 | The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.46 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leandre Odom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.